GGrantIndex
Sort

85,873 grants matching alzheimers

mGluR5 and Phase State Dependent Synaptic Loss in Alzheimer's Disease

$835,423
Stephen M Strittmatter · Yale University · R01 · FY2021 · AG

Therapeutic effects of APOE regulation via LNP-RNA formulations in Alzheimer's disease

$835,417
Yizhou Dong · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · AG

Quantitative MRI-based cerebral oxygen metabolism in Alzheimer's disease

$835,389
Yi Wang · Weill Medical Coll Of Cornell Univ · R01 · FY2023 · AG

Center to Accelerate Population Research in Alzheimer's (CAPRA)

$835,339
Julie Pw Bynum · University Of Michigan At Ann Arbor · P30 · FY2023 · AG

Mechanisms of cognitive impairment caused by atherosclerosis and red blood cell released ATP

$835,288
Pingnian He · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2024 · NS

Innate Immunity Stimulation Effects on Biomarkers, Cognition, and the Vascular Amyloid Proteome in a Squirrel Monkey Model of Sporadic CAA

$835,220
Henrieta Scholtzova · New York University School Of Medicine · R01 · FY2025 · NS

Novel automated performance-based ADL outcomes for early AD clinical trials

$835,178
Gad Asher Marshall · Brigham And Women'S Hospital · R01 · FY2020 · AG

Characterizing the evolution of Subjective Cognitive Decline in preclinical Alzheimer's disease

$835,070
Rebecca E Amariglio · Brigham And Women'S Hospital · R01 · FY2019 · AG

Presenilin1/gamma-secretase regulate the VEGFA/VEGFR2 brain angiogenesis inhibited by FAD mutants.

$834,945
Nikolaos Robakis · Icahn School Of Medicine At Mount Sinai · R56 · FY2023 · AG

Enhanced Quality in Primary Care for Elders with Diabetes and Dementia (EQUIPED-ADRD)

$834,894
Caroline S Blaum · New York University School Of Medicine · R33 · FY2018 · AG

Trial to Reduce Antimicrobial Use in Nursing home residents with Alzheimer's disease and other Dementias (TRAIN-AD)

$834,838
Susan L Mitchell · Hebrew Rehabilitation Center For Aged · R37 · FY2018 · AG

Robust detection of atrophy over short intervals in AD and FTLD

$834,693
Bradford C Dickerson · Massachusetts General Hospital · R01 · FY2024 · AG

Robust detection of atrophy over short intervals in AD and FTLD

$834,693
Bradford C Dickerson · Massachusetts General Hospital · R01 · FY2023 · AG

Role of N-terminal acetylation in alpha synuclein stability, function, and therapeutic targeting in synucleinopathies

$834,688
Elizabeth Rhoades · University Of Pennsylvania · R01 · FY2025 · NS

The cross-talk between a-Synucleinopathies and T cell immunity in ADRD

$834,685
Xiaobo Mao · Johns Hopkins University · R01 · FY2024 · AG

Theranostic CAR-T Targeting Senescence in Alzheimer's

$834,627
Lina Cui · University Of Florida · R61 · FY2025 · AG

Visual-somatosensory integration as a novel marker of Alzheimer's disease

$834,557
Jeannette R. Mahoney · Albert Einstein College Of Medicine · R01 · FY2022 · AG

ADNI Psychometrics

$834,522
Paul K Crane · University Of Washington · R01 · FY2020 · AG

Sex-specific trajectories in epigenomic regulation of brain patterning

$834,436
Flora M Vaccarino · Yale University · R01 · FY2025 · MH

Wisconsin Registry for Alzheimer's Prevention: Biomarkers for Preclinical AD

$834,297
Sterling C Johnson · University Of Wisconsin-Madison · R01 · FY2015 · AG

Neural Correlates of Apathy Across the Alzheimer's Disease Continuum

$834,296
Gad Asher Marshall · Massachusetts General Hospital · R01 · FY2023 · AG

Translational addiction neurobiology

$834,218
Elliot A Stein · National Institute On Drug Abuse · ZIA · FY2019 · DA

The wandering nerve: gateway to boost Alzheimer's disease related cognitive performance

$834,216
Heidi Irma Jacobs · Massachusetts General Hospital · R01 · FY2023 · AG

Role of Neurotrophins in the Development of the Mammalian Nervous System

$834,125
Lino Tessarollo · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA

Trial to Reduce Antimicrobial Use in Nursing home residents with Alzheimer's disease and other Dementias (TRAIN-AD)

$834,102
Susan L Mitchell · Hebrew Rehabilitation Center For Aged · R37 · FY2017 · AG